


Healthcare | Small Cap
Innova Captab Ltd shows a strong financial profile, marked by exceptional growth and profitability. The company is rapidly expanding its sales and profits while maintaining very healthy margins and returns for its investors. Its financial stability is a key strength, as it operates with very little debt, reducing risks associated with borrowing. This allows the company to reinvest its earnings back into the business. A notable area of focus is the company's operational efficiency; while it is growing its assets significantly, turning those assets into revenue is a developing aspect. It also takes a considerable amount of time to collect payments from customers. The future outlook appears positive, driven by aggressive growth strategies, though it is dependent on the successful utilization of its substantial new investments.
Innova Captab Ltd shows a strong financial profile, marked by exceptional growth and profitability. The company is rapidly expanding its sales and profits while maintaining very healthy margins and returns for its investors. Its financial stability is a key strength, as it operates with very little debt, reducing risks associated with borrowing. This allows the company to reinvest its earnings back into the business. A notable area of focus is the company's operational efficiency; while it is growing its assets significantly, turning those assets into revenue is a developing aspect. It also takes a considerable amount of time to collect payments from customers. The future outlook appears positive, driven by aggressive growth strategies, though it is dependent on the successful utilization of its substantial new investments.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
65.21
Industry Median
30.92
Small Cap Median
28.82
P/E RATIO
38.74
P/B RATIO
5.00
Industry Median
3.39
Small Cap Median
2.92
P/S RATIO
3.35
Industry Median
3.36
Small Cap Median
2.72
Others
PEG RATIO
1.19
EV/EBITDA RATIO
22.68
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹954.05 as on Aug 6, 2026.
The company is in a phase of exceptional and robust expansion. It is achieving outstanding growth in revenue, operating profits, and net income, indicating strong market demand and effective operational scaling. This high growth is supported by a significant increase in the company's asset base, reflecting aggressive investment in its future. The earnings available to each shareholder are also growing at an excellent rate, signaling that this expansion is creating substantial value.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 94.89 | 15.61 | 16.74 | 15.08 | 31.03 |
| Operating Profit Growth Rate | 77.78 | 18.75 | 35.09 | 20.78 | 30.65 |
| Earnings Per Share (EPS) Growth | 85.36 | -97.34 | 16.45 | 35.9 | 9.91 |
| Asset Growth Rate | 55.41 | 22.43 | 86.93 | 19.15 | 17.16 |
| Net Income Growth Rate | 88.24 | 6.25 | 38.24 | 36.17 | 10.16 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Amrutanjan Health Care Ltd | 8.25 | 73.76 | Highly Overvalued | 31.00 | 20.03 | 21.00 |
| 2 | Windlas Biotech Ltd | 7.52 | 27.76 | Neutral | 105.00 | 32.19 | 66.00 |
| 3 | Supriya Lifescience Ltd | 7.46 | 34.29 | Highly Overvalued | 294.00 | 25.98 | 209.00 |
| 4 | Aarti Pharmalabs Ltd | 7.46 | 35.92 | Neutral | 369.00 | 19.43 | 175.00 |
| 5 | Innova Captab Ltd | 7.36 | 38.74 | Overvalued | 243.00 | 14.63 | 141.00 |
| 6 | Aarti Drugs Ltd | 7.20 | 19.23 | Undervalued | 309.00 | 18.54 | 195.00 |
| 7 | Hikal Ltd | 7.13 | -55.92 | Neutral | 220.00 | -3.95 | -49.00 |
| 8 | RPG Life Sciences Ltd | 7.12 | 38.61 | Neutral | 147.00 | 69.64 | 115.00 |
| 9 | Morepen Laboratories Ltd | 7.12 | 45.91 | Neutral | 126.00 | 1.21 | 96.00 |
| 10 | Alembic Ltd | 7.06 | 7.01 | Undervalued | 90.00 | 4.85 | 317.00 |
| 11 | SMS Pharmaceuticals Ltd | 5.94 | 32.80 | Neutral | 171.00 | 9.35 | 102.00 |
| 12 | Gufic BioSciences Ltd | 5.49 | 63.18 | Neutral | 151.00 | 6.30 | 64.00 |
| 13 | Dishman Carbogen Amcis Ltd | 5.38 | 31.30 | Neutral | 566.00 | -2.45 | 97.00 |
| 14 | IOL Chemicals & Pharmaceuticals Ltd | 5.31 | 34.79 | Undervalued | 269.00 | 4.69 | 138.00 |
| 15 | Indoco Remedies Ltd | 5.26 | -21.52 | Neutral | 142.00 | -0.61 | -99.00 |
| 16 | Orchid Pharma Ltd | 4.85 | 246.31 | Neutral | 41.00 | 8.91 | 21.00 |
| 17 | Sequent Scientific Ltd | 4.61 | 313.39 | Overvalued | 162.00 | 1.74 | 32.00 |
| 18 | Sun Pharma Advanced Research Company Ltd | 4.35 | 4.53 | Neutral | 1599.00 | 47.83 | 1553.00 |
| 19 | Solara Active Pharma Sciences Ltd | 4.34 | -249.32 | Neutral | 187.00 | -1.50 | -7.00 |
| 20 | Zota Health Care Ltd | 3.97 | -58.38 | Neutral | 19.00 | 8.06 | -74.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Concall Report⬤2nd Feb 26
Q3 & 9M FY26 Earnings Conference Call
BULLISH SENTIMENT